Design and bioactivity evaluation of a novel autotaxin inhibitor with anti-hepatic fibrosis effects
Abstract Autotaxin (ATX) is considered as a serum marker of hepatic fibrosis, which is positively correlated with the degree of hepatic fibrosis. However, there are no clinical studies on anti-hepatic fibrosis drugs targeting ATX. This study attempts to find novel ATX small molecule inhibitors based...
Saved in:
| Main Authors: | Yuzheng Liu, Dan Luo, Hongwen Leng, Chaolun Gu, Qingrong Ding, Lin Zhao, Xinxin Chao, Hanxia Wang, Yueteng He, Silu Zhu, Guanhua Ai, Weijie Peng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-95464-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The validity of serum autotaxin as a predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease
by: Muhammad Abdel-Gawad, et al.
Published: (2023-10-01) -
A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis
by: Richell Booijink, et al.
Published: (2022-07-01) -
Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development
by: Silvia Anahi Valdés-Rives, et al.
Published: (2017-01-01) -
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
by: Kevin K Brown, et al.
Published: (2019-10-01) -
The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer
by: Ming Quan, et al.
Published: (2017-03-01)